Fentanyl transdermal - Acrux

Drug Profile

Fentanyl transdermal - Acrux

Alternative Names: Fentanyl MDTS

Latest Information Update: 03 Feb 2009

Price : $50

At a glance

  • Originator Acrux
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Jan 2009 Discontinued - Phase-I for Pain in Australia (Transdermal)
  • 14 Aug 2008 Phase I development is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top